logo
Plus   Neg
Share
Email

Dunelm Q4 Revenue, LFL Revenue Up; Sees Further Progress In Year Ahead

Dunelm Group plc (DNLM.L), a homewares retailer, Wednesday reported that its total fourth-quarter Group revenue increased 11.6 percent from last year to 264.1 million pounds.

Total like-for-like or LFL revenue increased 15.4 percent, reflecting strong underlying growth in stores and online. A weak comparator period last year and favourable weather this year benefited the results.

In its trading update for the 13-week period, the company said LFL store revenue increased 12.1 percent and LFL online revenue on Dunelm.com climbed 37 percent.

For fiscal 2019, total revenue grew 4.8 percent to 1 billion pounds, and LFL revenue increased 10.7 percent.

Looking ahead, Nick Wilkinson, Dunelm's Chief Executive Officer, said, "In the short-term, we remain cautious about the uncertain political climate and the impact it may have on consumer spending, but expect to make further progress in the year ahead and are confident about the Group's longer-term prospects."

Separately, Dunelm announced that Ian Bull has been appointed as a Non-Executive Director, with immediate effect. He will be a member of the Audit and Risk, Remuneration and Nominations committees.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>